Item 5. Other Information
Item 5. Other Information
None.
35
Table of Contents
Item 6. Exhibits
EXHIBIT INDEX
Exhibit No.
Description of Exhibit
2.1
Agreement and Plan of Merger and Reorganization, dated July 29, 2023, by and among Immunome, Inc., Ibiza Merger Sub, Inc. and Morphimmune, Inc. (incorporated by reference to Exhibit 2.1 to our Current Report on Form 8-K filed June 29, 2023).
3.1
Amended and Restated Certificate of Incorporation of Immunome, Inc. (incorporated by reference to Exhibit 3.1 to our Current Report on Form 8-K filed October 6, 2020).
3.2
Amended and Restated Bylaws of Immunome, Inc. (incorporated by reference to Exhibit 3.2 to our Current Report on Form 8-K filed October 6, 2020).
10.1
Form of Immunome, Inc. Stockholder Support Agreement, dated June 29, 2023 (incorporated by reference to Exhibit 10.1 to our Current Report on Form 8-K filed June 29, 2023).
10.2
Form of Morphimmume, Inc. Stockholder Support Agreement, dated June 29, 2023 (incorporated by reference to Exhibit 10.2 to our Current Report on Form 8-K filed June 29, 2023).
10.3
Form of Lock-Up Agreement, dated June 29, 2023 (incorporated by reference to Exhibit 10.3 to our Current Report on Form 8-K filed June 29, 2023).
10.4
Form of Subscription Agreement, dated June 29, 2023 (incorporated by reference to Exhibit 10.4 to our Current Report on Form 8-K filed June 29, 2023).
10.5
Employment Agreement, dated June 28, 2023, by and between Immunome, Inc. and Clay B. Siegall, Ph.D. (incorporated by reference to Exhibit 10.5 to our Current Report on Form 8-K filed June 29, 2023).
31.1*
Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2*
Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*
Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*
Certification of Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101
Interactive Data File (Form 10-Q for the Quarterly Period ended June 30, 2023 filed in XBRL). The financial information contained in the XBRL-related documents is "unaudited" and "unreviewed." The instance document does not appear in the interactive file because its XBRL tags are embedded within the Inline XBRL document.
104
Cover Page Interactive File (embedded within the Inline XBRL document).
*
Filed or furnished herewith.
# Management contracts or compensatory plans or arrangements
36
Table of Contents
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
IMMUNOME, INC.
(Registrant)
Date: August 9, 2023
By:
/s/ Purnanand D. Sarma
Name:
Purnanand D. Sarma, Ph. D.
Title:
President and Chief Executive Officer
(Principal Executive Officer)
Date: August 9, 2023
By:
/s/ Corleen M. Roche
Name:
Corleen M. Roche
Title:
Chief Financial Officer
(Principal Financial Officer)
37
Text extracted from the filing as submitted to EDGAR. Formatting, tables and exhibits are simplified for reading; the original document is authoritative for anything you rely on.